Uncategorized
Sustained-release dexamethasone decreased ocular itching, conjunctival redness in phase 2 trial
Patients treated with a single dose of sustained-release dexamethasone for allergic conjunctivitis demonstrated significantly lower ocular itching and conjunctival redness scores compared with subjects who received placebo over 6 weeks, according to an Ocular Therapeutix press release. The prospective, multicenter, randomized, double-masked phase 2 clinical trial evaluated 68 patients treated with OTX-DP (sustained-release dexamethasone) for reactions to a variety of allergens over 42 days. The primary outcome was a decrease in ocular itching and conjunctival redness at 14 days after administration.